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Abstract
Background: Tissue factor (TF), an initiator of blood coagulation, participates in cancer progression and metastasis.
We recently found that inhibition of MAPK/ERK upregulated both full length TF (flTF) and soluble isoform TF (asTF)
gene expression and cell-associated TF activity in breast cancer MDA-MB-231 cells. We explored the possible
mechanisms, especially the possible interaction with EGFR and PI3K/Akt pathways.
Methods: A plasmid containing TF promoter −2174 ~ +128 plus luciferase reporter gene was introduced into
MDA-MB-231 cells to evaluate TF promoter activity. In order to study the interaction of these pathways, ERK
inhibitor (PD98059), PI3K inhibitors (LY294002, wortmannin), Akt inhibitor (A6730), and EGFR inhibitor (erlotinib) as
well as the corresponding siRNAs were used to treat MDA-MB-231 cells, and ovarian cancer OVCAR-3 and SKOV-3
cells. Quantitative PCR and western blot were used to determine TF expression. One stage clotting assays were
used to measure pro-coagulation activity of the MDA-MB-231 cells.
Results: We show that PI3K inhibitors LY294002, wortmannin and A6730 significantly inhibited TF promoter
activity, and reduced TF mRNA and protein levels due to the inhibition of Akt phosphorylation. In contrast, ERK
inhibitor PD98059 and ERK siRNA enhanced TF promoter activity by 2.5 fold and induced an increase in TF mRNA
and protein levels in a dose dependent manner in these cells. The PI3K/Akt pathway was shown to be involved in
PD98059-induced TF expression because the induction was inhibited by PI3K/Akt inhibitors. Most interestingly, the
EGFR inhibitor erlotinib and EGFR siRNA also significantly suppressed PD98059- or ERK siRNA-induced TF promoter
activity and TF protein expression. Similar results were found with ovarian cancer cells SKOV-3 and OVCAR-3.
Furthermore, in MDA-MB-231, mRNA levels of asTF were regulated in a similar way to that of TF in response to the
cell treatment.
Conclusions: This study showed a regulatory mechanism in which MAPK/ERK signals inhibit EGFR/PI3K/Akt-mediated TF
expression in breast cancer MDA-MB-231 cells. The same regulation was observed in ovarian cancer OVCAR-3 and SKOV-3
cells. Interestingly, we observed that both flTF and asTF could be regulated in a parallel manner in MDA-MB-231. As the
PI3K/Akt pathway and EGFR regulate TF expression in cancer cells, targeting these signaling components is expected to
potentially inhibit TF expression-associated tumor progression.
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Pro-coagulation activity, Tumor invasiveness
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Background
Tissue factor (TF), a key molecule required to initiate
blood coagulation, is essential for embryo development,
maintenance of vascular integrity and tissue repair [1-4]. It
is widely expressed on cells of extravascular compartments
and initiates hemostasis upon tissue injury. TF expression
is a complicated and finely regulated process and studies
are still ongoing because the regulatory mechanisms of TF
expression are diversified in different cells such as endo-
thelial cells and cancer cells. Recent studies have demon-
strated that the binding of transcription factors to the TF
promoter region and the binding of miRNAs to its 3’ UTR
region both regulate TF expression [5,6].
A variety of cancer cells, such as breast cancer cells,
show aberrant high levels of TF expression. In colorectal
carcinoma cell lines, the activation of K-ras oncogene and
inactivation of p53, result in high levels of TF expression
in a manner dependent on MEK/mitogen-activated pro-
tein kinase (MAPK) and phosphatidylinositol 3-kinase
(PI3K) [7]. TF overexpression was also reported to be due
to amplified and active EGFR and depended mostly on ac-
tivation of JunD/AP-1 complex through PI3K/Akt and
JNK pathways [8]. The inhibition of TF promoter activity
by the ERK inhibitors U0126 and PD98059 had been
observed in breast cancer cells and LPS-stimulated human
monocytic cells [9,10]. Obviously, the roles of MAPK and
PI3K pathways depend on the species involved, particular
stimuli and the interaction of signal pathways [11]. It is
now well accepted that TF on tumor cells initiates PAR2-
dependent signaling with subsequent effects on tumor
growth and simultaneously induces thrombin generation
that facilitates metastasis [4].
The TF gene is composed of 6 exons and mature TF is a
trans-membrane protein of 263 amino acids (flTF). When
alternative TF pre-mRNA splicing occurs, exon 5 is
excluded during mRNA transcription and the transmem-
brane domain and C-terminal cytoplasmic domain of TF
are replaced by a different 40 amino acid peptide, resulting
in a shorter, 206 aa soluble TF (alternatively spliced, asTF)
[12,13]. The synthesis of asTF is determined by the binding
of specific Serine/arginine Rich (SR) Proteins to the exonic
splicing enhancer (ESE) within exon 5 [14]. The concen-
tration of asTF mRNA was reported to be about 30 fold
lower than flTF in endothelial cells and the inhibition of
PI3K/Akt reduced asTF mRNA in these cells [15]. More-
over, in addition to its potential role in thrombogenesis,
asTF binds to β1 and β3 integrins and induces angiogen-
esis [16]. Recent studies also indicated that asTF can
stimulate tumor angiogenesis by its binding to integrins
[17,18]. Clinical data showed that asTF was an indicator of
poor prognosis in lung cancer patients [18,19].
Given the importance of tissue factor on cancer cells,
this study focused on the roles of PI3k/Akt and MAPK/
ERK in the regulation of TF expression in MDA-MB-231
cells, especially the signaling crosstalk between the
MAPK/ERK and PI3K/Akt pathways. We also studied the
effects of TF expression on the activation of coagulation
and cell invasiveness, one of the critical steps of tumor
metastasis.
Methods
Cell lines and chemicals
Human breast cancer epithelial cell lines MDA-MB-231,
human ovarian epithelial cell lines SKOV-3 and OVCAR-3
were obtained from the American Type Culture Collection
(Rockville, MA, USA). Cells were cultured in Dulbecco's
modified Eagle’s medium(DMEM) supplemented with 10%
fetal bovine serum (FBS), 1%L-glutamine, and 1% sodium
pyruvate (all from Invitrogen, USA) at 37°C in a humidi-
fied atmosphere containing 5% CO2. To determine the
roles of MAPK/ERK and PI3K/Akt in TF expression,
PD98059 (Calbiochem, San Diego, USA), a selective in-
hibitor of MAPK/ERK kinase (MEK); LY294002 (Sigma-
Aldrich, USA) and wortmannin (Sigma-Aldrich, USA),
PI3K inhibitors; an Akt1/2 inhibitor A6730 (Sigma-
Aldrich, USA); erlotinib (TARCEVA, Genentech, USA), an
inhibitor of EGFR; an anti-EGFR antibody cetuximab
(Merck Serono, Switzerland), Akt siRNA(s659, s660), ERK
siRNA(s11140, s11141), EGFR siRNA(s564, s565) and
scrambled oligonucleotide (Applied biosystem, CA, USA)
were used to treat the cells for 24 h [19]. siRNA transfec-
tion was performed with INTERFERin (Polyplus-transfec-
tion SA, France) with the mixture of 2 siRNAs (2× 15 nM
of each siRNA) to knockdown one gene.
TF promoter activity analysis
MDA-MB-231 cells at 30%–40% confluence were trans-
fected with a constructed plasmid pGL4-TFluc, carrying
firefly luciferase reporter gene under the control of the
promoter of human TF within −2174~+128[20]. Trans-
fected cells were then selected by hygromycin (Invitro-
gen, USA) at the concentration of 400 μg/ml. Survived
clones of the cells were screened for bioluminescence in
the complete media supplemented with luciferase assay
system (Promega, USA) in FLUOstar Optima Microplate
Reader (Germany). The established cell line MDA-MB-
231-TFluc was used for evaluating the TF gene expres-
sion. After the treatment with the agents at the indicated
concentrations and time periods, the harvested cells were
washed, counted with trypan blue exclusion assay to
check the cell viability. The bioluminescence of the sam-
ples was then quantified for TF promoter activity. In our
experiments, the cells gave maximal luminescence level
at 24–48 h after the treatment (Figure 1a).
Quantitative polymerase chain reaction (qPCR) assay
The treated or non-treated cells were harvested and total
RNA was prepared by SV total RNA isolation system kit
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(Promega, USA). The purity of total RNA were checked
by a ratio of A260/A280 (>1.9). Total RNA (50 ng) was
used to synthesize cDNA in 20 μl reaction solution using
a kit of GoScript Reverse Transcription System (Pro-
mega, USA). Then 2 μl of cDNA was used for qPCR
assay in triplicates with taqmanW gene expression assay
method. The primers and probes for total human tissue
factor (Hs00175225_m1) and for the control TATA box
binding protein (TBP, Hs99999910_m1) were purchased
from Applied biosystem. The primers and the probes for
flTF (forward primer: TGATGTGGATAAAGGAG
AAAACTACTGT, reverse primer: CTACCGGGCTGT
CTGTACTCTTC, probe: FAM- TTCAAGCAGTGA
TTCCCTCCCGAACA–TAMRA); and asTF (forward
primer: GGGATGTTTTTGGCAAGGACTTA, reverse
primer: CCAGGATGATGACAAGGATGATG, probe:
FAM-AATCTTCAAGTTCAGGAA AGAAATATTCTA-
CATCATTGGA-TAMRA) were purchased from Euro-
gentec, Belgium [21]. The qPCR was performed by
10 min of initial denaturation and 44 cycles of 15 s at 95°
C, 60s at 60°C in a CFX96W Real-time System (BioRad).
Delta delta Ct method was used for analyzing qPCR
results.
Western blot
The cells were treated with 5–50 μM PD98059, 10 μM
LY294002, 0.1 μM wortmannin, 10 μM A6730, 0.1 μM
erlotinib, and 50 nM cetuximab or 30 nM of the mixture
of siRNA for indicated time periods and washed 3 times.
Cell lysates was obtained by incubating the cells in a lysis
buffer [10 mM Tris pH 6.8, 1 mM EDTA, 10% NP40,
1 mM PMSF, 1% SDS plus protease inhibitor cocktail
and phosphotase inhibitor cocktail 2 (Sigma) on ice for
30 min. Cell debris was removed by centrifugation at
16000 g for 10 min. Protein concentration was deter-
mined by a BCATM protein assay kit (Thermo Scientific,
USA). Fifty microgram protein of each sample was
loaded on 8% of SDS-PAGE gel for electrophoresis, and
the protein was transferred onto polyvinylidene flroride
(PVDF) membrane by the iBlotTM dry blotting system
(Invitrogen, USA). The membranes were blocked by 5%
nonfat dry milk for 1 h and incubated with either mono-
clonal anti-TF antibody (# 4509, American Diagnostica,
USA), or anti-phospho-Akt (Ser473) antibody or anti-
Akt polyclonal antibody (# 9271 and 9272, cell signaling,
USA) at 4°C for overnight, then the membranes were
washed with Tris Buffered Saline-tween 20 (TBS-tween)
buffer for 1 h and incubated with appropriate horserad-
ish peroxidase (HRP)-conjugated secondary antibodies
(Invitrogen, USA) diluted in blocking buffer for one hour
at room temperature. After washing, western blotting
luminol reagent (Santa Cruz Biotechnology, USA) was
added onto the membranes and the chemiluminescence
was recorded in a Fuji LAS-3000 system. Then the
Figure 1 TF promoter activity in MDA-MB-231-TFluc cells treated by LY294002, wortmannin and PD98059. Panel a: MDA-MB-231-TFluc
cells were treated by PD98059 at 10 μM for different time periods, then washed. Panels b-c: the cells were treated by LY294002 (b), wortmannin
(c) and PD98059 (d) at indicated concentrations for 24 hrs. The activity of luciferase in the cells was measured. The data represent the means
values of three independent experiments.
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membranes were treated with antibody stripping buffer
(Gene Bio-application Ltd. Israel), and incubated with
anti-actin antibody (1:4000 dilution, Sigma, USA) and
secondary antibodies for control. The results of western
blot were quantified with Gel-Pro Analyzer software
version 4.0.00.001 (Media Cybernetics, Bethesda, MD,
USA).
One stage clotting assay
MDA-MB-231 cells were treated for 24 h with 10 μM of
PD98059, 10 μM of LY294002, 0.1 μM of wortmannin,
or DMSO as control. Then the cells harvested with non-
enzymatic detachment method were washed 3 times and
suspended in barbital buffer at 105/ml. Coagulant activity
was tested at 37°C by adding 50 μl of cells to 100 μl of
citrated normal plasma and 100 μl of 0.25 M CaCl2. The
clotting time for each sample was determined from the
addition of CaCl2 to the formation of first fibrin strand.
The assay included a standard curve made with
thromboplastin at the dilutions of 1:25 (100% activity),
1:50, 1:100, 1:200, 1:400, and 1:800. The cell membrane-
associated TF activity determined with the clotting time
was converted to thromboplastin procoagulant activity
units (neoplastin, Stago, Asnières, France). The result is
presented as percentage of the change in comparison
with control cells. All the experiments were performed
at least 3 times and each experiment was in triplicates.
Matrigel invasion assay
MDA-MB-231 cells were treated with 10 μM of
PD98059, 10 μM of LY294002, 0.1 μM of wortmannin or
control DMSO for 24 h. The cells were washed 3 times
and 0.5 ml of the cells (5 × 104/ml) were seeded into each
upper chamber of 24-well matrigel-coated invasion
chamber and 0.75 ml DMEM supplemented with 5%
fetal bovine serum was added into the lower chamber
(BD Biosciences, USA). The invasion chambers were
incubated for 22 h according to the manufacture’s proto-
col. Then the non-invading cells were removed from the
upper surfaces of membranes by scrubbing with cotton
tipped swabs and the cells on the lower surfaces of the
membrane were fixed with 100% methanol and stained
with 1% toluidine blue, the invading cells numbers were
counted under an inverted microscope, and the invasion
index were obtained by calculating the averages of the
number of the cells per observation field of each sample
in comparison with the control groups. The experiments
was performed with 6 samples for one condition and
repeated 3 times.
Statistical analyses
Data were analyzed by Student’s t-test, one-way ANOVA
and Mann–Whitney U test as appropriate. The data of
qPCR and invasion assay are presented as mean± SEM.
The rest of data is presented as mean ± SD. A probability
value ≤0.05 was regarded as significant.
Results
TF promoter activity down-regulated by PI3K pathway
inhibitors and up-regulated by ERK inhibitor
To facilitate evaluating TF gene expression, we con-
structed a sub-cell line MDA-MB-231-TFluc, selected by
antibiotic hygromycin resistance, which carries TF pro-
moter that drives luciferase gene. The sub-cell lines
showed a constitutive luminescence around 5×104 channel
numbers compared to the background levels of 30–50
channel numbers of the negative control parental cells.
PI3K inhibitors LY294002 and wortmannin, showed
significant inhibitory effect on the TF promoter activity
in MDA-MB-231-TFluc cells. As demonstrated in the
decreased bioluminescent levels, TF promoter-driven
luciferase activity was inhibited by both inhibitors (IC50=
8.8 μM for LY294002 and IC50=0.12 μM for wortmannin)
(Figure 1b, 1c). The inhibition of TF promoter activity was
statistically significant and in a dose dependent manner
for these two agents. Furthermore, the inhibitory effect of
both agents was observed within the dose ranges of inhibi-
tory activity as reported in the literature, showing that the
effects were specific.
In contrast, ERK inhibitor PD98059 dramatically
enhanced TF promoter-driving luciferase activity in the
cells. A peak of activity was observed after 24 h treat-
ment (Figure 1a). This enhancement was statistically sig-
nificant, dose dependent and observed within the
published dose range of its inhibitory effect on ERK.
TF mRNA and TF protein down-regulated by PI3K
pathway inhibitors and up-regulated by ERK inhibitor
According to the obtained results, MDA-MB-231 cells
were treated with 10 μM LY294002 and 0.1 μM wortman-
nin. The qPCR and western blotting analysis showed that
both LY294002 and wortmannin induced a remarkable
decrease in TF mRNA and protein levels (Figure 2a,c).
In contrast, PD98059 treatment enhanced dose-depend-
ently tissue factor mRNA and protein levels in the cells
(Figure 2a,b,c). qPCR assay with ERK siRNA confirmed
the effect of PD98059 (Figure 2a). These results were
well correlated with the data of luminescence assay.
Blockage of PI3K/Akt pathway suppressed PD98059-
induced high level of TF transcription
We examined the relationship between PI3K and ERK
pathways in the regulation of TF promoter in MDA-MB-
231-TFluc cells. The MDA-MB-231-TFluc cells were
treated by PD98059 in the presence of LY294002 or of
wortmannin and the luminescence levels were determined.
The results showed that both PI3K inhibitors could signifi-
cantly suppress the PD98059-induced reporter gene
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expression (Figure 3a). Then MDA-MB-231 cells were
treated in a similar way and their TF mRNA levels were
quantified by qPCR method. The results showed that
LY294002 and wortmannin as well as Akt inhibitor A6730
significantly suppressed PD98059-enhanced TF mRNA
trnascription (Figure 3b). As Akt phosphorylation is a
down-stream event of the activated PI3K, pAkt was
checked in MDA-MB-231 cells. We found that pAkt level
was enhanced by PD98059 treatment and this enhanced
pAkt level was significantly inhibited by LY294002, showing
a close relationship between ERK inhibition and Akt phos-
phorylation (Figure 3c).
Involvement of EGFR in PD98059-enhanced high level of
TF transcription
Gan Y et al. have suggested that EGFR activity was
involved in ERK inhibition-induced activation of PI3K/Akt
pathway [22]. We used EGFR inhibitor erlotinib together
with PD98059 to the culture of the MDA-MB-231-TFluc
cells. The results confirmed the inhibition of PD98059-
enhanced cell luminescence by erlotinib (Figure 4a). The
results of qPCR also showed a significant inhibition of TF
transcription by both erlotinib and anti-EGFR antibody
cetuximab (Figure 4b). Western blot further confirmed the
results of luminescence and qPCR by showing that erloti-
nib, like the inhibitors for PI3K/Akt suppressed signifi-
cantly the PD98059-induced high level of TF protein
synthesis (Figure 4c, d). We also noticed that erlotinib did
not significantly affect TF protein level of the cells in culture
without PD98059 induction. These data strongly indicated
the involvement of EGFR was involved in PD98059-induced
TF expression.
Cell procoagulant and invading capacities correlated with
TF expression
To assess the relationship between the modulation of TF
expression and cell-associated procoagulant activity, we
performed one stage clotting assay with the microparticle-
free MDA-MB-231 cells. We found that LY294002 and
wortmannin inhibited the cell procoagulant activity, and
that PD98059 induced an augmentation of the cell pro-
coagulant activity (Figure 5a). These results indicated that
the effect of LY294002, wortmannin and PD98059 on TF
activity could be functionally relevant to cell’s pro-coagulant
activity. They further suggested that the changes in TF ex-
pression on MDA-MB-231 might be related to the
changes in cell invasion capacity through Matrigel matrix
(Figure 5b).
TF regulation in SKOV-3 and OVCAR-3
As EGFR was shown to be involved in the regulation of
cell-associated TF expression, we performed the experi-
ments of western blot with two EGFR positive cell lines
SKOV-3 and OVCAR-3. The results showed that PD98059
Figure 2 Expression levels of TF mRNA and TF protein in treated MDA-MB-231 cells. Panel a: The qPCR results of total TF mRNA levels in
treated MDA-MB-231 cells. The cells were treated for 24 hr by the indicated agents at the indicated concentrations. qPCR was performed with
primers Hs00175225_m1. The results were obtained from three independent experiments. Statistical significance (p<0.05) was found for all of the
groups in comparison with the control group, except for the group of 5 μM PD98058. Panel b: The western blot of TF protein levels in
PD98059-treated cells, showing a dose dependent increase in TF levels at 24 hrs. Panel c: The western blot of TF protein levels in the cells treated
by LY294002 (10 μM) and wortmannin (0.1 μM) at 24 hrs. The data of the ratio were obtained with 3 repeated blots. * : p<0.05 in comparison
with the controls.
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upregulated TF synthesis in these two cell lines. Further-
more, Akt siRNA and EGFR siRNA suppressed PD98059-
enhanced TF expression in these two cell lines in a similar
manner to that in MDA-MB-231 (Figure 5c). We also per-
formed qPCR to evaluate mRNA levels of asTF in these
cells. asTF mRNA was found to represent about 2–5% of
total TF mRNA. The results showed that PD98059 treat-
ment stimulated asTF mRNA levels in all of the three cell
lines, however, the blockage of Akt by A6730 and the
blockage of EGFR by erlotinib and siRNA affected
PD98059-enhanced asTF mRNA levels only in MDA-MB-
231, but not in SKOV-3 and OVCAR-3 cells.
Discussion
In this study, TF expression was studied with pharmaco-
logical inhibitors and siRNA that suppress PI3K/Akt and
MAPK/ERK pathways [23]. Previous reports showed that
these two pathways regulate both flTF and asTF tran-
scription [15,24,25].
In agreement with other reports [7,8], an essential role
of PI3K/Akt in TF expression in MDA-MB-231 cells was
found because treatment by either LY294002 or wort-
mannin decreased TF expression in a dose-dependent
manner. Experiments using Akt siRNA gave the same
results. This was demonstrated by a decrease in the re-
porter gene expression using MDA-MB-231 cells trans-
fected with the plasmid PGL4-TFluc as well as by qPCR
using the parental cells. The decrease in TF gene expres-
sion was well correlated with the decrease in flTF pro-
tein and with the decrease in the cell surface-associated
TF activity as shown by plasma clotting assays. We fur-
ther showed that treatment with LY294002 and wort-
mannin resulted in inhibition of the catalytic activity of
PI3K and Akt phosphorylation by western blot. All these
findings confirmed that PI3K/Akt phosphorylation plays
a critical role in TF gene expression.
In contrast to Akt inhibitors, we found that treatment
with the ERK inhibitor PD98059 surprisingly resulted in
a remarkable increase in TF gene expression in a dose-
and time-dependent manner. This finding was initially
observed in MDA-MB-231-TFluc cells, and then con-
firmed by qPCR and western blot with their parental
cells. The use of ERK siRNA further confirmed this ob-
servation. Therefore, Akt and ERK modulated TF ex-
pression in opposite ways.
To study the mechanisms involved, we blocked PI3K/
Akt activation by LY294002, wortmannin, A6730 or Akt
siRNA in PD98059-treated MDA-MB-231 cells. These
experiments gave concomitant results showing that
PD98059-induced TF expression was indeed inhibited at
mRNA and protein levels by blocking the PI3K/Akt
pathway, and in particular, the blockage was complete
using Akt inhibitor A6730. These results emphasized the
Figure 3 TF promoter activity, TF mRNA and Akt
phosphorilation after combined treatments. Panel a:
MDA-MB-231-TFluc cells were treated by 10 μM of LY294002 and 0.1
μM of wortmannin, in the absence or the presence of 10 μM PD98059
for 24 hrs. The activity of luciferase was measured. The data was
represented as means±SEM of three independent experiments.
* : p<0.05. Panel b: qPCR results of TF mRNA (Hs00175225_m1) in the
cells after the treatment for 24 hrs by 10 μM of LY294002, 10 μM of
A6730, 0.1 μM of wortmannin, in the absence or the presence of 10 μM
PD98059. The experiments were repeated for 3 times. ** : p<0.05.
Panel c: MDA-MB-231 cells were treated with 0.1 μM of wortmannin,
10 μM of LY294002 in the presence or the absence of PD98059 at 10 μM
or 50 μM for 24 hrs. Total protein was extracted for the determination of
pAkt level by western blot using anti-Akt or anti-pAkt antibodies. The
data were from three blots. * : p<0.05.
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importance of the PI3K/Akt pathway in the control of
TF expression.
In the literature, many studies reported the interaction
of growth factor receptors with ERK and PI3K/Akt path-
ways and the crosstalk between ERK and PI3K/Akt path-
ways [26-31]. Gan et al. demonstrated that blockage of
ERK activity enhanced EGF receptor activation and turn-
over, which in turn enhanced PI3K activation and Akt
phosphorylation [22]. For this reason, we explored the
role of EGFR in the PD98059-induced TF up-regulation.
Our results from qPCR and western blot experiments
showed that the EGFR inhibitor erlotinib indeed suppressed
PD98059-induced TF expression. We also observed that
the inhibitory effect of erlotinib was much more noteworthy
in PD98059-treated cells than in non-treated cells. The
experiments using EGFR siRNA gave similar results. These
results strongly suggest that the similar regulation described
by Gan et al. occurred in MDA-MB-231 cells [22]. In brief,
the inhibition of ERK activity by PD98059 enhanced EGFR
activity, which in turn up-regulated Akt activity, resulting in
high levels of TF expression. Such a mechanism can
explain how the blockage of ERK induced a high level of
TF expression, and why blockage of the Akt pathway sup-
pressed such an induction. The same profile of TF regula-
tion was again observed in OVCAR-3 and SKOV-3 cells,
suggesting a widespread mechanism. Our results do not
exclude other signal interconnections and we believe that
the full mechanism of TF regulation is likely more compli-
cated and further study is needed. Our results contradict a
previous report showing inhibition of TF expression by
ERK inhibitor [9], however, the reason for this discrepancy
is unclear.
As the inhibition of PI3K/Akt may reduce asTF mRNA
in endothelial cells [15], we evaluated the asTF isoform
in response to the addition of inhibitors of PI3K/Akt and
MAPK/ERK. We observed in MDA-MB-231, SKOV-3
and OVCAR-3 cells that PD98059 up-regulated asTF.
However, the inhibition of PD98059-enhanced asTF
mRNA transcription by Akt inhibitors was observed only
in MDA-MB-231. The results of the asTF mRNA levels
in SKOV-3 and OVCAR-3 cells seem to suggest that
asTF level could also be regulated independently from
Figure 4 TF promoter activity, TF mRNA and Akt phosphorilation after combined treatments. Panel a: MDA-MB-231-TFluc cells were
treated by 0.1 μM of erlotinib in the absence or the presence of 10 μM PD98059 for 24 hrs. The cell activity of luciferase was measured. The data
was from three independent experiments. Panel b: qPCR results of TF mRNA in the cells after the treatment for 24 hrs by 50 nM of cetuximab or
0.1 μM of erlotinib in the absence or the presence of 10 μM PD98059. The data were from 3 independent experiments. * : p<0.05. Panel c: The
western blots of TF protein in the cells treated for 24 hrs by 10 μM PD98059, 10 μM of A6730, 50 nM of cetuximab and 0.1 μM of erlotinib. The
data were from 3 blots. * : p<0.05 in comparison with control. Panel d: The western blots of TF protein in the cells treated for 24 hrs by 10 μM
LY294002, 0.1 μM erlotinib and 10 μM A6730 in the presence or the absence of 10 μM PD98059. The data were from 3 blots. * : p<0.05.
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flTF expression [15]. They indicate the complexity of the
regulation of TF isoform transcription. Further investi-
gation is needed to clarify these. Our observation in
MDA-MB-231 also suggests that the increase in the
membrane-associated flTF and in the secretion of asTF
can occur concomitantly during malignant transformation.
flTF is known to stimulate tumor progression via FVIIa
and PAR2 and asTF has been shown to induce tumor
angiogenesis by its binding to integrins [16]. The level of
asTF was found to be related to poor clinical prognostics
[17]. The secretion of asTF by cancer cells has been shown
to be a complex process which is under the control of SR
proteins in addition to TF promoter and miRNA regula-
tion [15,31], Further investigation can be expected to
Figure 5 Cell-associated procoagulant activity and invasion in MDA-MB-231 cells, flTF expression and asTF mRNA transcription in
SKOV-3 and OVCAR-3 cells. Panel a: Cell procoagulant activity. MDA-MB-231 cells were treated with 10 μM of PD98059, 10 μM of LY294002,
0.1 μM of wortmannin for 24 hrs and washed. Then clotting time was measured with these cells after the addition of human blood plasma and
calcium. The results represent 3 different experiments. * : p<0.05 between PD98059 group versus LY294002 and wortmannin groups. Panel b:
Cell invassive capacity : the same cells as in the panel a were cultured in the invasion chambers for 22 hrs. The cells penetrated through the
matrigel were counted in microscopy. The data were from 3 independent experiments. * : P<0.05 in comparison to the control cells. Panel c:
Regulation of TF protein in SKOV-3 and OVCAR-3 cells. SKOV-3 and OVCAR-3 cells were treated 10 μM of PD98059 with or without A6730 and
EGFR siRNA for 24 hrs. The protein was extracted from the washed cells and examined for TF expression by western blot. The data were from 3
repeated blot experiments. Significant difference was found between the PD98059 group versus all of the other groups within the same cells
(p<0.05). Panel d: asTF levels in PD98059 treated cells. The cells were treated by 10 μM of PD98059 with or without 0.1 μM erlotinib 10 μM
A6730 and EGFR siRNA for 24 hrs. qPCR data were from 3 dependent experiments. * : p<0.05 for PD98059 groups in comparison with all of the
other groups in the same cell lines.
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better understand the regulation of TF including its iso-
forms in detail. Our results do not exclude a distinct SR
protein-mediated regulatory mechanism for asTF produc-
tion which has been reported to be independent from
transcriptional regulation for TF [15].
Our results support and underline the roles of Akt and
EGFR in TF-related tumor growth and metastasis. We
believe that targeting TF expression could potentially im-
prove clinical cancer therapy by inhibiting tumor angio-
genesis and metastasis as well as by controlling
thrombotic complications [32,33].
Conclusions
This study showed a regulatory mechanism in which
MAPK/ERK signals inhibit EGFR/PI3K/Akt-mediated TF
expression in breast cancer MDA-MB-231 cells. The same
regulation was observed in ovarian cancer OVCAR-3 and
SKOV-3 cells. We also showed that both flTF and asTF
could be regulated in a parallel manner. As the PI3K/Akt
pathway and EGFR regulate TF expression in cancer cells,
targeting these signaling components is expected to poten-
tially inhibit TF expression-associated tumor progression.
Abbreviation
MAPK: Mitogen-activated protein kinase/Extracellular signal-regulated kinase;
ERK: Extracellular signal-regulated kinases; PI3K: Phosphoinositide 3-kinase;
AKT: Akt1 or protein kinase B (PKB); siRNA: Small interfering RNA;
EGFR: Epidermal growth factor receptor; qPCR: Quantitative polymerase chain
reaction.
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